Australia's ALS rises after Morningstar ups fair value estimate on supportive industry trends

ALS

01/04/2026 01:50

Updates

** Shares of Australia's ALS ALQ.AX rise as much as 5.3% to A$21.90, the highest level since March 13

** Analysts at Morningstar increase fair value estimate for ALS by 4% to A$16.70

** Investment research firm estimates ALS's FY26 underlying NPAT of A$354 million ($243.84 million), a 15% growth from FY25

** Morningstar remains at the high-end of recently upgraded FY26 organic revenue growth guidance of 6%-8% for the testing services provider

** Tightening regulations and energy transition add to the tailwind for ALS, Morningstar says

** 10 out of 13 analysts rate the stock "Buy" or higher, 2 "Hold", and 1 "Sell"; set the median PT at A$24.70 - data compiled by LSEG

** ALQ down 1.8% YTD, including the day's moves

($1 = 1.4518 Australian dollars)

(Reporting by Keshav Singh Chundawat & Rajasik Mukherjee in Bengaluru)

((Keshav.singhchundawat@thomsonreuters.com))